Ras-related C3 botulinum toxin substrate 1 (RAC1) P29S mutant (RAC1 P29S)

Ras-related C3 botulinum toxin substrate 1 (RAC1) P29S is a recurrent gain-of-function mutation of the RAC1 small GTPase, identified as a significant driver in cutaneous melanoma (Krauthammer et al., 2012; PubMed: 22941190). The P29S substitution occurs in the switch I region, transforming the protein into a 'fast-cycling' GTPase that spontaneously loads GTP independently of guanine nucleotide exchange factors (Davis et al., 2013; PubMed: 23533172). This constitutive activation triggers downstream signaling pathways, including the MAPK and PI3K/AKT pathways, which promote uncontrolled cell proliferation and survival (Hodis et al., 2012; PubMed: 22817889). It also plays a critical role in actin remodeling, which enhances the metastatic and invasive potential of cancer cells. In clinical settings, the RAC1 P29S mutation is frequently associated with resistance to standard-of-care BRAF and MEK inhibitors (Watson et al., 2014; PubMed: 24631838). This makes the mutant protein a high-priority target for precision medicine to overcome drug resistance in melanoma patients. While direct pharmacological inhibition of RAC1 is challenging due to its high affinity for GTP, several small-molecule inhibitors and combination strategies are currently under investigation (Lionarons et al., 2019; PubMed: 31142540). Targeting the RAC1 P29S mutant represents a strategy to treat a specific subset of patients who lack effective long-term therapeutic options.

Other names

RAC1 p.P29Sp.Pro29SerMelanoma-associated RAC1 mutantRAC1 P29S mutant protein

Direct inhibition of GTP binding or displacement of GTP, inhibition of interaction with downstream effectors like PAK1, or stabilization of the inactive GDP-bound state.